Four new products will help Novo Nordisk division grow

Over the next three years, four medicines against rare diseases will help bring the Danish pharmaceutical company’s destitute division for rare diseases to the same growth level as others, the area head says.

Ludovic Helfgott, executive vice president and head of Rare Disease at Novo Nordisk | Photo: PR / Novo Nordisk

After a name change and a focus realignment, Novo Nordisk’s former Biopharma unit, now its Rare Disease division, is training its sights on future growth.

Danish business daily Børsen reports that Novo Nordisk Rare Disease is aiming to launch four new products meant to regain growth for the division over the next three years.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs